Arca
Skip to content
Tools
Tools

EPHA2: Ephrin type-A receptor 2

Receptor tyrosine kinase which binds promiscuously membrane- bound ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells.

  • Drugs that act on it: 2
  • Approved: 2
  • In phases 1 to 3: 0
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on EPHA2, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2

Approved2

  • Regorafenib
  • Dasatinib anhydrous

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        RegorafenibBoxed warningApprovedBayerSmall moleculeInhibitorEphrin type-A receptor 2 inhibitor96
        Dasatinib anhydrousApprovedChia Tai Tianqing Pharmaceutical GroupSmall moleculeInhibitorEphrin type-A receptor 2 inhibitor0

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid TumorsRegorafenibPhase 1 / Phase 2Not yet recruitingCSPC Megalith Biopharmaceutical Co.,Ltd.Oct 5, 2026
        Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast CancerRegorafenibPhase 2Not yet recruitingFujian Cancer HospitalAug 14, 2026
        A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal CancerRegorafenibPhase 1 / Phase 2Not yet recruitingCSPC Megalith Biopharmaceutical Co.,Ltd.Aug 6, 2026
        A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and IrinotecanRegorafenibPhase 3Not yet recruitingSichuan Baili Pharmaceutical Co., Ltd.Jul 28, 2026
        IBI363 Combined With Bevacizumab for Advanced Colorectal CancerRegorafenibPhase 3RecruitingInnovent Biologics (Suzhou) Co. Ltd.Jul 23, 2026
        Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat SyndromeRegorafenibPhase 2Not yet recruitingXiang-QianJul 9, 2026
        A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and PimitespibRegorafenibPhase 2RecruitingGlaxoSmithKlineJul 8, 2026
        Clinical Study of Novel Therapeutic Vaccine for Advanced Solid TumorsRegorafenibPhase 1RecruitingWest China HospitalMay 5, 2026

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        Early-onset posterior polar cataract
        0.77
        Total early-onset cataract
        0.77
        Early-onset non-syndromic cataract
        0.68
        Neurodegenerative disease
        0.56
        Medullary thyroid gland carcinoma
        0.54
        Neoplasm
        0.54
        Hereditary disease
        0.41

        Genes and related targets

        Complexes and families that share a gene with this target
        Genes
        EPHA2

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2068, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P29317, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.